The largest database of trusted experimental protocols

Eye Drops

Eye drops are a common form of medication used to treat a variety of eye conditions, such as dry eye, glaucoma, and eye infections.
They are typically applied directly to the surface of the eye, allowing for targeted delivery of the active ingredients.
This MeSH term provides a concise overview of the uses, administration, and potential benefits of eye drops.
Researchers and clinicians can use this information to better understand the role of eye drop therapies in ophthalmic care and make informed decisions about their use in clinical practice and research.
The description includes key details about eye drop formulations, common indications, and the importance of proper administration technique.
This information can help optimie the research and development of new eye drop products to address unmet needs in ocular health.

Most cited protocols related to «Eye Drops»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Anti-Antibodies Anticholinergic Agents Biopsy Conjunctiva, Bulbar Conjunctival Diseases Diagnosis Dry Eye Syndromes Eye Drops Lymphocyte Phenotype Sialadenitis Sjogren's Syndrome
All animal procedures were conducted in accordance with the Association for Research in Vision and Ophthalmology (ARVO) statements on the care and used of animals in ophthalmic research. Adult male rd1 mice (>6 weeks of age) were anaesthetised by intraperitoneal injection of ketamine (72 mg/kg) and xylazine (16 mg/kg). The pupils were fully dilated with 1% tropicamide and 2.5% phenylephrine eye drops, and a custom-made ultrafine needle (Hamilton RN needle, 34 gauge) was attached to a 5 μl Hamilton glass syringe and passed at 45 degrees through the pars plana into the vitreous cavity (for intravitreal delivery) or into the subretinal space without retinal perforation (for subretinal delivery). Injections were performed under direct visualisation of the needle tip using an operating microscope (Leica Microsystems), avoiding lenticular contact and blood vessels. Each eye received a total intravitreal dose of 1E+14 genome copies in a 3 μl volume or 2 μl subretinal bleb (6 eyes per vector).
Publication 2021
Adult Animals Blood Vessel Cloning Vectors Dental Caries Eye Eye Drops Genome Injections, Intraperitoneal Ketamine Lens, Crystalline Males Mice, House Microscopy Needles Obstetric Delivery Phenylephrine Planum Poly(ADP-ribose) Polymerases Pupil Retinal Perforations Syringes Tropicamide Vision Xylazine
Each subject’s head was stabilized using a chin and forehead rest similar to those found on standard clinical imaging instruments. There was no pupil dilation or control of accommodation using eye drops. A previously described AOSLO was used to image the parafoveal cone mosaic of the right eye.28 (link), 29 (link) The wavelength of the super luminescent diode used for retinal imaging was 775nm, subtending a field of view of 0.96° x 0.96°. The system’s pupil used for imaging was 7.75mm, however the eye’s pupil was undilated and certainly less than this. We thus calculated that the 30μm confocal pinhole of our system was one Airy disk diameter or less. Separate image sequences of 150 frames each were acquired at four parafoveal locations, each approximately 0.65° from the center of fixation (Figure 1). The four parafoveal locations were imaged in a random order, with the subject staying positioned on the chin/forehead rest for each set of four image sequences. Randomization of the imaging order had two potential benefits. First, the image quality may be best at the first location imaged when the tear film might be more evenly distributed across the cornea (though subjects were instructed to blink normally during each imaging set). Second, the randomized order would mitigate any effect in decreased fixational stability over the course of the imaging session, which might result from fatigue. This procedure was repeated 10 times for each subject with a short break after each set of four locations. The image acquisition software had an “active blink removal” algorithm, which discarded frames that had a mean intensity below a specified threshold. This process improved the percentage of frames in the recorded image sequence (always 150 frames) that contained useable retinal image data.
To correct for intraframe distortions within the frames of the raw image sequence due to the sinusoidal motion of the resonant optical scanner, we estimated the distortion from stable images of a Ronchi ruling, and then re-sampled each frame of the raw image sequence over a grid of equally spaced pixels. After desinusoiding, a reference frame was manually selected from within each image sequence, for subsequent registration using custom software. Registration of frames within a given image sequence was performed using a “strip” registration method, in which the frames were registered by dividing the frame of interest into strips, aligning each strip to the location in the reference frame that maximizes the normalized cross correlation between them.30 Once all the frames were registered, the 40 frames with the highest normalized cross correlation to the reference frame were averaged, in order to generate a final registered image with an increased signal to noise ratio for subsequent analysis.
Publication 2012
Blinking Chin Cornea Eye Drops Fatigue Forehead GART protein, human Head Luminescence Mydriasis Ocular Accommodation Pupil Reading Frames Retina Retinal Cone Sinusoidal Beds Tears
Mice were anesthetized with a mixture of xylazine (6 mg/kg) and ketamine (100 mg/kg), and pupils were dilated with topical drops of Cyclomydril (Alcon Laboratories, Fort Worth, TX). Two minutes after pupil dilation, lubricating eye drops (Alcon Laboratories) were applied to the cornea. The fundus was viewed with an imaging camera, and laser photocoagulation was induced using the image-guided laser system (Micron IV, Phoenix Research Laboratories, Pleasanton, CA). The fundus image as well as the aiming beam can be observed on the monitor screen. Four laser burns at equal distance from the optic nerve were induced one by one in each eye by a green Argon laser pulse with a wavelength of 532 nm, a fixed diameter of 50 μm, duration of 70 ms, and varying power levels from 180 mW to 360 mW. If necessary, an orienting laser shot can also be generated approximately three times of the diameter of the optic nerve to help determine the relative positions of the lesions in an eye. After laser photocoagulation, the eyes were gently rinsed with sterile saline to remove the lubricating eye drops and treated with an antibiotic ointment, erythromycin (Fougera, Melville, NY). Mice were then placed on a pre-warmed warming plate at 35°C after the laser treatment until they awakened.
Full text: Click here
Publication 2015
Antibiotics Argon Ion Lasers Burns Cornea Erythromycin Eye Eye Drops Ketamine Light Coagulation Lubricant Eye Drops Mice, House Mydriasis Ointments Optic Nerve Pulse Rate Pupil Saline Solution Sterility, Reproductive Xylazine
In the clinic, a detailed parental interview was conducted, including questions regarding family income and preschool or daycare enrollment.11 (link) The examination, described in detail elsewhere,11 (link),12 (link) included VA testing, evaluation of ocular alignment, cycloplegic refractive error measurement, and anterior segment and dilated fundus evaluations. Cycloplegic refraction was performed with the Retinomax Autorefractor (Right Manufacturing, Virginia Beach, VA) at least 30 minutes after instilling the second of 2 drops of 1% cyclopentolate given 5 minutes apart. Cycloplegic retinoscopy was performed if Retinomax readings with confidence ratings of ≥8 were not obtained in both eyes after 3 attempts per eye. If parents refused cycloplegic eyedrops, non-cycloplegic retinoscopy was performed.
Presenting monocular distance VA measurement was attempted using an electronic visual acuity (EVA) tester6 (link) with the ATS protocol.5 (link) The EVA system uses a handheld device programmed with the protocol algorithm to control the presentation of high-contrast black-and-white single HOTV optotypes framed by crowding bars spaced a half-letter width from the letter on a 17-inch monitor. The ATS testing algorithm has been described previously;5 (link),6 (link) an initial screening phase obtaining an approximate VA threshold is followed by a first threshold determination phase, a reinforcement phase, and a second threshold determination phase. The VA score, measured in 0.1 logMAR increments from 20/800 to 20/16, is the smallest logMAR level passed in either of the two threshold phases.
The VA testing protocol specific to MEPEDS has been reported in detail.3 (link) Children were seated 3 meters from the monitor with a lap card containing the single-surround HOTV letters. Children who had difficulty comprehending the task underwent a binocular pretest at near, which if passed was followed by a binocular pretest at 3 meters, and monocular threshold testing for those able to complete the pretests. Children were instructed to identify the letter on the monitor verbally or by pointing to the matching optotype on the hand-held card; those who knew their letters were still encouraged to refer to the card. The right eye was tested first, followed by the left, with the fellow eye occluded with an adhesive patch or, rarely, occluding glasses. Testing was attempted on all children, including those with developmental delay or disability.
Publication 2009
ARID1A protein, human Child Child, Preschool Cyclopentolate Cycloplegics Day Care, Medical Disabled Persons Eye Drops Eyeglasses Medical Devices Ocular Refraction Parent Refractive Errors Reinforcement, Psychological Retinoscopy Vision Visual Acuity

Most recents protocols related to «Eye Drops»

Example 3

Penl-XBIR3 eyedrops were delivered immediately after RVO and at 24 h. At 48 h, the eyes were imaged via OCT.

FIG. 4 presents images from individual animals (2 control, 2 RVO, 4 RVO+Penl-XBIR3). For each animal there are three sets of OCT and brightfield images. The brightfield image has a horizontal line showing the level of the OCT.

Four hours after RVO, mouse retinas were harvested for western blot to detect activated caspase-9 (c1Casp9) (FIG. 5, left panel). The blot showed a 10-fold induction of c1Casp9.

To show target engagement, after RVO, mice were given Penl-XBIR3 and retinas were harvested and immunoprecipitated with anti-His followed by western blot for clCasp9 (FIG. 5, right panel). There was a 21-fold increase in binding of XBIR3 and clCasp9 by 4 h and a 45-fold increase by 24 h.

Full text: Click here
Patent 2024
Animals Caspase 9 Caspase 10 Eye Eye Drops Mus Retina Western Blot

Example 5

TUNEL staining is a marker of cell death. RVO induces TUNEL staining by 24 h in the INL. Retinas were harvested at 48 h from mice treated with Penl-XBIR3 or untreated mice, then processed for immunohistochemistry. Analysis of samples showed that TUNEL positive cells were decreased by Penl-XBIR3 eyedrops and that the eyedrops maintained INL thickness (FIG. 11).

Full text: Click here
Patent 2024
Cell Death Cells Eye Drops Immunohistochemistry In Situ Nick-End Labeling Mus Retina

Example 1

The ability of eyedrops to deliver Penl-XBIR3 in mice and rats was tested. Results are presented in FIG. 2 and FIG. 3.

In mice, Penl-XBIR3 (10 μg) eyedrops were applied, then the animals were sacrificed at the indicated times. In rabbits, 200 μg Penl-XBIR3 eyedrops or a saline vehicle were administered BID for 4.5 days. The final dose given 5 h prior to harvest of retinas. Plasma from rabbits obtained at baseline and harvest.

Retinal lysates were immunoprecipitated with XIAP, followed by western blotting for anti-His. XBIR3 contains a His tag, so uptake of XBIR3 is detectable using anti-His. Blots for the mouse and rabbit samples, along with graphs quantifying the results, are presented in FIG. 2. XBIT3 uptake was observed in both mouse and rabbit samples. Uptake in the mouse samples was detected by 1 h and maintained through 24 h. In rabbit there was significant XBIR3 in retina at 5d.

Baseline and post-treatment plasma from rabbits was analyzed by immunoprecipitation with XIAP followed by western blot with anti-His. A Ponceau protein stain was used to show input protein amounts. XBIR3 was not detected in rabbit plasma (FIG. 3), indicating that it remains localized in the eye.

Full text: Click here
Patent 2024
Animals Eye Drops Immunoprecipitation Mice, House Oryctolagus cuniculus Plasma Proteins Rabbits Rattus Retina Saline Solution Stains Western Blotting
Not available on PMC !

Example 4

The efficacy of Penl-XBIR3 eyedrops in RVO was evaluated. Penl-XBIR3 eyedrops were given immediately after RVO and at 24 h. At 48 h OCT images showed significant protection against RVO (FIG. 6) with less increase in retinal thickness and abrogation of retinal detachment (**P<0.01).

Individual retinal layers were also examined, as they are not affected equally by RVO. Retinal layers include the ganglion cell layer (GCL), the inner plexiform layer (IPL), the inner nuclear layer (INL), the outer plexiform layer (OPL), the outer nuclear layer (ONL), the inner segments (IS), the outer segments (OS), and the retinal pigment epithelium (RPE), which is located next to the choroid. Penl-XBIR3 decreased retinal detachment (FIG. 7, **P<0.01), protected the inner retinal layers (FIG. 8, **P<0.01), decreased swelling of the outer retina layers, such as the outer plexiform layer (FIG. 9, **P<0.01) and protected the photoreceptors (FIG. 10, *P<0.05, **P<0.01).

Full text: Click here
Patent 2024
Cells Choroid Eye Drops Ganglia Photoreceptor Cells Retina Retinal Detachment Retinal Pigment Epithelium Retinitis
Initially, an intracanalicular ointment infiltration (IOI) treatment with an ophthalmic corticosteroid/antibiotic combination (tobramycin and dexamethasone eye ointment; TobraDex; Alcon) was adopted for all patients, which was a safe and non-invasive approach that was initially introduced by Xu et al (9 (link)). Specifically, the discharges and concretions were expressed thoroughly, followed by lacrimal duct irrigation with physiological saline. Subsequently, ~0.2 ml antibiotic/corticosteroid eye ointment was injected into the lacrimal duct weekly for 2-8 weeks and topical antibiotic eye drops were administered four times a day.
A total of five patients who responded poorly to IOI underwent routine surgical treatment. First, a silicone Crawford tube (Shandong Bausch & Lomb Freda Pharmaceutical Co., Ltd.,) was intubated into the lacrimal passage through the upper and lower lacrimal puncta under topical anesthesia. Using probe guidance, an incision was made on the canaliculus, parallel to the eyelid margin and at a distance of 2 mm from the punctum. The canalicular lumen was exposed to remove intracanalicular dacryoliths and hyperplastic granulation tissue. After that, the canalicular incision was closed with an 8-0 absorbable thread. Subsequently, the lacrimal duct was irrigated and injected with 0.2 ml antibiotic/corticosteroid eye ointment. Irrigation and injection with eye ointment were performed weekly for 2-8 weeks after surgery. In addition, the patients were treated with topical antibiotic eye drops four times daily. The silicone drainage tube remained in place for 3-6 months.
Publication 2023
Administration, Ophthalmic Adrenal Cortex Hormones Antibiotics Dexamethasone Drainage Duct, Lacrimal Eye Drops Eyelids Granulation Tissue Hyperplasia Lacrimal Punctum Ointments Operative Surgical Procedures Patients Pharmaceutical Preparations physiology Saline Solution Silicones TobraDex Tobramycin Topical Anesthetics

Top products related to «Eye Drops»

Sourced in Japan, Ireland, China, United States
Cravit is a laboratory equipment product. It is used for conducting scientific experiments and analyses.
Sourced in Japan, China, United States
Oxybuprocaine hydrochloride eye drops is a topical anesthetic solution used to numb the surface of the eye. It contains the active ingredient oxybuprocaine hydrochloride, which works by blocking the transmission of pain signals from the eye to the brain.
Sourced in United States, Ireland, Germany, Canada
Vigamox is an ophthalmic solution used in the treatment of bacterial conjunctivitis. It contains the active ingredient moxifloxacin hydrochloride, a broad-spectrum fluoroquinolone antibiotic.
Sourced in United States, Belgium, Switzerland, Greece, Spain, Japan, United Kingdom, Egypt
Tobradex is a topical ophthalmic medication that contains a combination of tobramycin, an antibiotic, and dexamethasone, a corticosteroid. It is used to treat various eye conditions that require both antibiotic and anti-inflammatory treatment.
Sourced in Japan, United States, China
Levofloxacin eye drops is a topical ophthalmic solution containing the antibiotic levofloxacin. It is intended for the treatment of bacterial conjunctivitis.
Sourced in United States, Belgium, Japan, Australia, China
Alcaine is a topical ophthalmic solution. It contains the active ingredient proparacaine hydrochloride, which is a local anesthetic used to numb the eye's surface.
Sourced in Japan, China, Belgium, Germany
Tropicamide is a mydriatic and cycloplegic agent used in ophthalmic examinations and procedures. It is a pharmaceutical product designed to temporarily dilate the pupil and temporarily paralyze the ciliary muscle, which controls the eye's focusing ability.
Sourced in Japan, Germany
Mydrin-P is a laboratory product used for ophthalmic purposes. It functions as a mydriatic agent, intended to dilate the pupil.
Sourced in United States, Ireland
Pred Forte is a prescription eye drop solution that contains the active ingredient prednisolone acetate. It is a corticosteroid medication used to reduce inflammation in the eye.
Sourced in United States, Belgium
Tobramycin is a broad-spectrum aminoglycoside antibiotic used for the treatment of various bacterial infections. It is a laboratory product designed for research and clinical applications.

More about "Eye Drops"

Eye Drops: Optimizing Ocular Care Eye drops are a versatile form of medication used to address a wide range of eye conditions, from dry eye syndrome to glaucoma and eye infections.
These topical formulations are designed for direct application to the surface of the eye, allowing for targeted delivery of active ingredients and enhanced therapeutic efficacy.
Ophthalmic eye drops come in various forms, including solutions, suspensions, and ointments.
Common active ingredients found in eye drops include antibiotics (e.g., Levofloxacin, Tobramycin), anti-inflammatory agents (e.g., Pred Forte), and lubricants (e.g., Cravit, Vigamox).
These specialized eye drops can help alleviate symptoms, manage chronic conditions, and prevent or treat eye infections.
Proper administration technique is crucial for ensuring the optimal effectiveness of eye drop therapies.
Patients should be instructed on how to properly instill eye drops, such as tilting the head back, gently pulling the lower eyelid down, and applying the drops without touching the eye or dropper to the eye.
Correct dosing and frequency are also important factors in achieving the desired therapeutic outcomes.
Researchers and clinicians can leverage the wealth of information available on eye drops to make informed decisions about their use in clinical practice and research.
By understanding the formulations, indications, and administration techniques, they can optimize the development and utilization of these essential ophthalmic products to address unmet needs in ocular health and improve patient outcomes.
Whether you're investigating new eye drop therapies, comparing existing products, or seeking to optimize your research and development process, tools like PubCompare.ai can help you streamline your efforts and make data-driven decisions.
By harnessing the power of AI-driven comparisons and comprehensive literature reviews, you can identify the most promising eye drop protocols and products to advance your work in the field of ocular care.